Glevo is an antimicrobial drug of the fluoroquinolone group.
Release form and composition
Dosage forms Glevo - film-coated tablets and solution for iv administration.
The composition of the tablets:
- 250 or 500 mg of levofloxacin (in the form of hemihydrate);
- Auxiliary components: microcrystalline cellulose, povidone (K-30), magnesium stearate, crospovidone, starch;
- The composition of the film shell: titanium dioxide, dibutyl phthalate, hypromellose, talc, macrogol, iron dye red oxide.
Glevo tablets are sold in 5 pcs. in blisters, 1 or 5 blisters per pack.
1 ml of infusion solution contains:
- 5 mg of levofloxacin hemihydrate;
- Additional substances: sodium hydroxide, diluted hydrochloric acid, disodium edetate, sodium chloride, water for injection.
Glevo solution is realized in bottles of 100 ml.
Indications for use
In accordance with the instructions to Glevo, the drug is intended for the treatment of infectious and inflammatory diseases, the pathogens of which are microorganisms sensitive to levofloxacin. In particular, the medicine is prescribed for infections:
- ENT organs;
- Lower respiratory tract, including in community-acquired pneumonia and exacerbation of chronic bronchitis;
- Genital organs;
- Abdominal cavity (in combination with drugs that have an effect on anaerobic microflora);
- Skin and soft tissues, including furunculosis, festering atheroma and abscess;
- The urinary tract and kidneys, including prostatitis and acute pyelonephritis.
Application Glevo contraindicated:
- Pregnant women;
- In case of hypersensitivity to levofloxacin, any auxiliary component or other fluoroquinolones;
- During the period of breastfeeding;
- If there is a history of indications of tendon damage during quinolone therapy;
- Children and teenagers under 18;
- With epilepsy.
Careful observation during the Glevo treatment period is necessary for older people (because in old age there is a high probability of the presence of concomitant renal dysfunction), as well as for patients with deficiency of glucose-6-phosphate dehydrogenase.
Dosing and Administration
According to the instructions to Glevo, in the form of a solution, the drug must be administered by slow intravenous infusion. The specific dosage and frequency of injections depend on the type of infection, the sensitivity of the pathogen and the severity of the disease. Duration of administration: for a dose of 250 mg - at least 30 minutes, for a dose of 500 mg - at least 60 minutes. If the patient's condition allows, after several days of treatment, he is transferred to oral medication.
Glevo tablets should be taken 1-2 times a day before meals or between meals. Dosages are also determined individually.
As a rule, Glevo is prescribed in both dosage forms:
- With sinusitis - 500 mg once a day for 10-14 days;
- With prostatitis - 500 mg once a day for 28 days;
- In community-acquired pneumonia, 500 mg once or twice a day, the course lasts from 7 to 14 days;
- With exacerbation of chronic bronchitis - 250-500 mg once a day for 7-10 days;
- For urinary tract infections: uncomplicated - 250 mg once a day for 3 days, complicated - at the same dose, only the course lasts 7-10 days;
- In case of infections of the abdominal cavity, Glevo is administered 500 mg / day for 7-14 days, and anti-bacterial preparations are also prescribed that act on anaerobic flora;
- With infections of the skin and soft tissues, the dose of the drug is 250 or 500 mg, respectively, once or twice a day. The course is 7-14 days.
Patients with impaired liver function require dose adjustment based on creatinine clearance.
The duration of application of the left is determined by the normalization of body temperature and reliable eradication (destruction) of the pathogen. However, after this treatment with the drug, like any other antibiotic, it is recommended to continue for another 48-78 hours.
Possible adverse reactions on the part of the body when applying Glevo:
- Nausea, vomiting, indigestion, abdominal pain, diarrhea (sometimes with blood), loss of appetite, increased activity of hepatic transaminases, pseudomembranous enterocolitis, dysbacteriosis, hepatitis, hyperbilirubinemia;
- Decrease in blood pressure, prolongation of the QT interval, tachycardia, vascular collapse, atrial fibrillation;
- Headache, insomnia or drowsiness, dizziness, general weakness, paresthesias, anxiety, tremor, hallucinations, fear, confusion, movement disorders, depression, in predisposed patients - epileptic seizures;
- Hypoglycemia, manifested by increased appetite, increased sweating, tremors, nervousness;
- Interstitial nephritis, hypercreatininemia, acute renal failure;
- Violations of smell, hearing, vision, tactile and taste sensitivity;
- Muscle weakness, tendonitis, tendon rupture, myalgia, arthralgia, rhabdomyolysis;
- Hemolytic anemia, hemorrhages, thrombocytopenia, agranulocytosis, pancytopenia, leukopenia, eosinophilia, neutropenia;
- Itching and flushing of the skin, urticaria, edema of the skin and mucous membranes, bronchospasm, toxic epidermal necrolysis, Stevens-Johnson syndrome (malignant exudative erythema), allergic pneumonitis, anaphylactic shock, asphyxiation, vasculitis.
Glevo can also cause persistent fever, exacerbation of porphyria, photosensitivity, asthenia, and the development of superinfection.
With the same active ingredient release the following drugs:
- Levolet R;
Terms and conditions of storage
It is recommended to store Glevo at a temperature up to 25 ºС in the place where the sun's rays cannot penetrate. Shelf life - 2 years. The opened bottle with solution is not subject to storage.